Stock listing
BMV:TEVAN Teva Pharmaceutical Industries Limited Acciones
Mexican listing (BMV) of Teva Pharmaceutical Industries Limited · home listing TASE:TEVA
Follow Teva Pharmaceutical Industries Limited into a list and get an email when it puts out news.
Home listing price · TASE:TEVA
13,330 ILA (agorot) -590 (-4.2%)
Close on Nov 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, TASE:TEVA
- Day range
- 13,260 – 13,780 ILA (agorot)Nov 19, 2026
- Volume
- 1.09M sharesNov 19, 2026
- Market cap
- 155.5B ILSAt the close on Nov 19, 2026 · price × 1.17B shares outstanding
- 52-week range
- 7,915.00 – 14,440 ILA (agorot)Lowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- 164.5M ILSMedian day 1.05M shares · 5 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TASE:TEVA · Home | 13,330 ILA (agorot) | -590 (-4.2%) | 1,091,163 | 13,780 | 13,780 | 13,260 | 13,920 | Close on Nov 19, 2026 |
| NYSE:TEVA | $39.23 USD | +0.69 (+1.8%) | 6,809,187 | $38.46 | $39.91 | $38.30 | $38.54 | Close on Nov 20, 2026 |
| B3:T1EV34 | 122.30 BRL | -1.80 (-1.5%) | 4 | 122.30 | 122.30 | 122.30 | 124.10 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · TASE:TEVA · ILA (agorot), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 13,330 | -590 | -4.2% | 13,780 | 13,780 | 13,260 | 1,091,163 | |
| 13,920 | +240 | +1.8% | 13,820 | 14,070 | 13,820 | 822,689 | |
| 13,680 | -470 | -3.3% | 13,890 | 13,900 | 13,580 | 924,287 | |
| 14,150 | +180 | +1.3% | 14,300 | 14,440 | 14,150 | 1,641,795 | |
| 13,970 | +430 | +3.2% | 13,770 | 14,030 | 13,740 | 1,570,791 | |
| 13,540 | +50 | +0.4% | 13,580 | 13,820 | 13,450 | 1,303,243 | |
| 13,490 | -90 | -0.7% | 13,580 | 13,600 | 13,400 | 1,143,841 | |
| 13,580 | +280 | +2.1% | 13,520 | 13,840 | 13,470 | 1,433,958 | |
| 13,300 | +120 | +0.9% | 13,350 | 13,390 | 13,160 | 1,028,753 | |
| 13,180 | 0 | 0.0% | 13,130 | 13,340 | 13,020 | 14,956,833 | |
| 13,180 | -390 | -2.9% | 13,100 | 13,260 | 12,900 | 2,733,286 | |
| 13,570 | +490 | +3.7% | 12,770 | 13,570 | 12,700 | 2,946,686 | |
| 13,080 | +280 | +2.2% | 13,040 | 13,120 | 12,310 | 3,585,767 | |
| 12,800 | +80 | +0.6% | 12,810 | 12,910 | 12,730 | 1,021,023 | |
| 12,720 | +110 | +0.9% | 12,380 | 12,790 | 12,380 | 1,308,939 | |
| 12,610 | +360 | +2.9% | 12,320 | 12,660 | 12,210 | 1,519,647 | |
| 12,250 | -70 | -0.6% | 12,180 | 12,270 | 12,010 | 1,351,741 | |
| 12,320 | -90 | -0.7% | 12,410 | 12,490 | 12,250 | 1,253,715 | |
| 12,410 | -170 | -1.4% | 12,520 | 12,600 | 12,390 | 1,152,711 | |
| 12,580 | -270 | -2.1% | 12,730 | 12,770 | 12,190 | 2,111,248 | |
| 12,850 | -80 | -0.6% | 12,890 | 13,070 | 12,760 | 978,093 | |
| 12,930 | +110 | +0.9% | 13,000 | 13,050 | 12,820 | 1,057,342 | |
| 12,820 | -110 | -0.9% | 12,930 | 12,930 | 12,740 | 507,479 | |
| 12,930 | -10 | -0.1% | 12,560 | 12,990 | 12,540 | 1,008,583 | |
| 12,940 | +200 | +1.6% | 12,730 | 12,940 | 12,620 | 971,415 | |
| 12,740 | +110 | +0.9% | 12,610 | 12,780 | 12,530 | 980,586 | |
| 12,630 | +630 | +5.3% | 12,610 | 12,730 | 12,550 | 1,611,466 | |
| 12,000 | +230 | +2.0% | 11,980 | 12,060 | 11,910 | 671,471 | |
| 11,770 | -220 | -1.8% | 11,880 | 11,990 | 11,770 | 1,291,493 | |
| 11,990 | -20 | -0.2% | 11,900 | 12,090 | 11,820 | 1,153,909 | |
| 12,010 | +10 | +0.1% | 12,200 | 12,200 | 12,000 | 1,216,909 | |
| 12,000 | -160 | -1.3% | 12,120 | 12,150 | 12,000 | 853,894 | |
| 12,160 | 0 | 0.0% | 12,160 | 12,160 | 12,160 | 0 | |
| 12,160 | -150 | -1.2% | 12,200 | 12,300 | 12,140 | 892,287 | |
| 12,310 | +340 | +2.8% | 12,100 | 12,310 | 12,080 | 1,011,870 | |
| 11,970 | +130 | +1.1% | 12,000 | 12,040 | 11,920 | 879,177 | |
| 11,840 | -210 | -1.7% | 11,900 | 11,930 | 11,750 | 669,308 | |
| 12,050 | 0 | 0.0% | 12,050 | 12,050 | 12,050 | 0 | |
| 12,050 | -10 | -0.1% | 11,760 | 12,060 | 11,730 | 1,570,387 | |
| 12,060 | +20 | +0.2% | 11,890 | 12,080 | 11,780 | 1,262,779 | |
| 12,040 | +80 | +0.7% | 12,040 | 12,150 | 11,870 | 1,541,251 | |
| 11,960 | 0 | 0.0% | 11,960 | 11,960 | 11,960 | 0 | |
| 11,960 | 0 | 0.0% | 11,960 | 11,960 | 11,960 | 0 | |
| 11,960 | +160 | +1.4% | 11,780 | 11,960 | 11,600 | 1,562,605 | |
| 11,800 | +90 | +0.8% | 11,900 | 11,990 | 11,640 | 1,135,971 | |
| 11,710 | +170 | +1.5% | 11,690 | 11,900 | 11,660 | 1,124,143 | |
| 11,540 | +420 | +3.8% | 11,190 | 11,600 | 11,180 | 950,706 | |
| 11,120 | 0 | 0.0% | 11,120 | 11,120 | 11,120 | 0 | |
| 11,120 | -10 | -0.1% | 11,200 | 11,260 | 11,030 | 1,052,520 | |
| 11,130 | +210 | +1.9% | 11,070 | 11,250 | 10,960 | 1,048,196 | |
| 10,920 | +10 | +0.1% | 10,920 | 11,020 | 10,680 | 1,086,826 | |
| 10,910 | -50 | -0.5% | 10,970 | 11,050 | 10,820 | 499,288 | |
| 10,960 | -40 | -0.4% | 11,090 | 11,090 | 10,900 | 473,654 | |
| 11,000 | -10 | -0.1% | 11,310 | 11,450 | 10,970 | 983,311 | |
| 11,010 | -10 | -0.1% | 10,870 | 11,530 | 10,820 | 1,791,302 | |
| 11,020 | +310 | +2.9% | 10,820 | 11,030 | 10,780 | 1,141,409 | |
| 10,710 | -320 | -2.9% | 10,940 | 11,000 | 10,660 | 905,060 | |
| 11,030 | -180 | -1.6% | 11,020 | 11,140 | 10,980 | 1,399,391 | |
| 11,210 | +50 | +0.4% | 11,160 | 11,280 | 11,120 | 812,651 | |
| 11,160 | -50 | -0.4% | 11,250 | 11,440 | 11,010 | 740,192 | |
| 11,210 | +120 | +1.1% | 11,090 | 11,230 | 11,050 | 1,192,310 | |
| 11,090 | +70 | +0.6% | 11,180 | 11,220 | 11,040 | 727,266 | |
| 11,020 | -80 | -0.7% | 11,030 | 11,070 | 10,930 | 285,212 | |
| 11,100 | -110 | -1.0% | 11,150 | 11,190 | 11,030 | 625,182 | |
| 11,210 | +130 | +1.2% | 10,950 | 11,240 | 10,850 | 937,718 |
Splits
2 splits since 2002 · TASE:TEVA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split | |
| 2-for-1 | Split |
- Ticker
- BMV:TEVA/N
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- BMV
- Currency
- MXN
What changed lately
Latest news release · Oct 1, 2026
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
Latest earnings call · Nov 3, 2026
Teva Pharmaceutical Industries (TASE:TEVA) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 3, 2026
Q3 2026 Earnings Presentation
Earnings · 70 slides
Latest news
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
Oct 1, 2026
Closed 12,160 (-1.2%) on Oct 1, 2026
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
Sep 28, 2026
Closed 11,970 (+1.1%) on Sep 29, 2026
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
Sep 23, 2026
Closed 12,050 (-0.1%) on Sep 24, 2026
Teva Releases Q3 2026 Aide Memoire
Sep 23, 2026
Closed 12,050 (-0.1%) on Sep 24, 2026
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
Sep 14, 2026
Closed 11,540 (+3.8%) on Sep 14, 2026
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
Sep 10, 2026
Closed 11,120 (-0.1%) on Sep 10, 2026
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
Jun 18, 2026
Closed 9,432.00 (+1.8%) on Jun 19, 2026
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
Jun 8, 2026
Closed 10,190 (+2.3%) on Jun 8, 2026
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
Jun 5, 2026
Closed 10,190 (+2.3%) on Jun 8, 2026
Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
Jun 4, 2026
Closed 9,869.00 (+5.7%) on Jun 4, 2026
Teva Pharmaceutical Industries Limited on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 41 in the last 12 months · 90 in all · newest Oct 1, 2026 · oldest 2025
- Calls
- 32 calls with a replay · 32 with a transcript · latest Nov 3, 2026
- Decks
- 167 decks · latest Nov 3, 2026
Where Teva Pharmaceutical Industries Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TASE:TEVA · Home listing | TASE | Israel | ILA |
| NYSE:TEVA | NYSE | United States | USD |
| gettex:TEV | gettex | Germany | EUR |
| Frankfurt:TEV | Frankfurt | Germany | EUR |
| Tradegate:TEV | Tradegate | Germany | EUR |
| BOATS:TEVA | BOATS | United States | USD |
| OTC:TEVJF | OTC | United States | USD |
| LS Exchange:883035 | LS Exchange | Germany | EUR |
| B3:T1EV34 | B3 | Brazil | BRL |
| BMV:TEVAN · This page | BMV | Mexico | MXN |
| VIE:TEVA | Vienna | Austria | EUR |
| BX Swiss:TEV | BX Swiss | Switzerland | CHF |
| LSIN:0LER | LSIN | United Kingdom | USD |
| Stuttgart:TEV | Stuttgart | Germany | EUR |
| Hanover:TEV | Hanover | Germany | EUR |
| Lang & Schwarz:883035 | Lang & Schwarz | Germany | EUR |
| BSESOF:TEV | BSESOF | Bulgaria | EUR |
| Dusseldorf:TEV | Dusseldorf | Germany | EUR |
| Hamburg:TEV | Hamburg | Germany | EUR |
| Munich:TEV | Munich | Germany | EUR |
Valuation
P/E 89.8× against a median of 29.7×: 10th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 19, 2026
- Enterprise value
- 155.3B ILS
- P/E
- 89.8×
- EV/sales
- 3.3×
- EV/EBITDA
- 13.5×
- Price/book
- 5.8×
- Gross margin
- 66.1%
- Operating margin
- 17.3%
- Net margin
- 3.7%
- Debt to equity
- 0.5×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Limited · TASE:TEVA | US$46.34B | US$46.29B | 89.8× | 3.3× | 13.5× | 5.8× | 3.7% | 0.5× | n/a |
| argenx SE · EURONEXT:ARGX | US$58.86B | US$53.72B | 22.8× | 6.5× | n/a | 7.0× | 31.4% | 0.0× | n/a |
| Roche Holding Ltd · SIX:RO | US$51.16B | US$77.45B | 3.3× | 1.1× | 2.9× | 1.3× | 20.9% | 1.0× | n/a |
| Sun Pharmaceutical Industries Limited · NSE:SUNPHARMA | US$48.81B | US$45.53B | 41.2× | 6.8× | 24.4× | 5.1× | 17.8% | 0.0× | n/a |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A · SSE:600276 | US$45.00B | US$38.46B | 33.8× | 7.8× | n/a | 4.5× | 27.0% | 0.0× | n/a |
| Sandoz Group Ltd · SIX:SDZ | US$41.49B | US$46.45B | 43.3× | 4.2× | 23.6× | 4.6× | 8.6% | 0.7× | n/a |
| Celltrion, Inc. · KRX:068270 | US$36.08B | US$35.44B | 30.8× | 9.7× | 25.9× | 2.7× | 32.2% | 0.0× | n/a |
| Zoetis Inc. · NYSE:ZTS | US$32.69B | US$40.21B | 13.0× | 4.2× | 10.2× | 9.9× | 26.4% | 2.7× | 0.69 |
| Divi's Laboratories Limited · NSE:DIVISLAB | US$32.03B | US$32.03B | 101× | 26.4× | 74.8× | 17.7× | 26.1% | 0.0× | n/a |
| Hansoh Pharmaceutical Group Company Limited · HKEX:3692 | US$23.78B | US$18.80B | 28.5× | 8.3× | 21.6× | 4.2× | 37.0% | 0.1× | n/a |
| United Therapeutics Corporation · NASDAQ:UTHR | US$23.63B | US$21.56B | 19.2× | 6.8× | 15.2× | 3.8× | 38.6% | 0.0× | 0.46 |
| Median of the others | US$38.78B | US$39.33B | 29.7× | 6.8× | 22.6× | 4.5× | 26.7% | 0.0× | 0.57 |
Forecasts
Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 11.00 ILA · Analysts' mean
- Revenue, year to Dec 2026
- 16.79B · 12 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Richard Francis | President and Chief Executive Officer, Member of the Board of Directors |
| Edward Jordan | EVP and head of Commercial Operations North America |
Board
| Director | Role |
|---|---|
| Sol J. Barer | Chairman of the Board Independent Director |
| Amir Elstein | Independent Director |
| Chen Lichtenstein | Independent Director |
| Gerald M. Lieberman | Independent Director |
| Perry D. Nisen | Independent Director |
| Richard Francis | President and Chief Executive Officer, Member of the Board of Directors |
| Roberto A. Mignone | Independent Director |
| Ronit Satchi-Fainaro | Independent Director |
| Rosemary A. Crane | Independent Director |
| Tal Zaks | Independent Director |
Events
- Next results
- Jan 27, 2027 (expected)
Calls
All 32 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · Before open | +3.8% |
| Q1 2025 | May 7, 2025 · Before open | +0.8% |
| Q4 2024 | Jan 29, 2025 · Before open | −14.8% |
| Q3 2024 | Nov 6, 2024 · Before open | −4.3% |
| Q2 2024 | Jul 31, 2024 · Before open | +4.2% |
| Q1 2024 | May 8, 2024 · Before open | +13.0% |
| Q4 2023 | Jan 31, 2024 · Before open | +3.9% |
| Q3 2023 | Nov 8, 2023 · Before open | −0.3% |
| Q2 2023 | Aug 2, 2023 · Before open | +13.2% |
| Q1 2023 | May 10, 2023 · Before open | −8.0% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2022 | Feb 8, 2023 · Before open | −3.7% |
| Q3 2022 | Nov 3, 2022 · Before open | −2.5% |
| Q2 2022 | Jul 26, 2022 · After close | +21.1% |
| Q1 2022 | May 3, 2022 · Before open | +1.9% |
| Q4 2021 | Feb 9, 2022 · Before open | +10.5% |
| Quarter to Sep 30, 2021 | Oct 27, 2021 · Before open | −6.7% |
| Quarter to Jun 30, 2021 | Jul 28, 2021 · Before open | +12.0% |
| Quarter to Mar 31, 2021 | Apr 28, 2021 · Before open | −1.9% |
| Quarter to Dec 31, 2020 | Feb 10, 2021 · Before open | −9.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 70 slides | Nov 3, 2026 |
| Corporate Update (October 2026) | Corporate update | 15 slides | Oct 9, 2026 |
| IL-15 Celiac Disease Phase 2a Topline Results - Conference Call (September 2026) | Conference | 23 slides | Sep 2, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 74 slides | Jul 29, 2026 |
| Technical Presentation (July 2026) | Technical | 19 slides | Jul 7, 2026 |
| Technical Presentation (July 2026) | Technical | 18 slides | Jul 7, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 73 slides | Apr 29, 2026 |
| Corporate Update (February 2026) | Corporate update | 25 slides | Feb 17, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 71 slides | Jan 28, 2026 |
| 44th Annual J.P. Morgan Healthcare Conference 2026 | Conference | 20 slides | Jan 13, 2026 |
Show 50 decks
This page holds 50 of 167 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Senior notes Announced: about US$4.9B Use of proceeds: Redeem certain existing notes, pay related fees and expenses, and general corporate purposes including repaying outstanding debt | Sep 10, 2026 |
| Senior notes (EUR and USD-denominated) Made bigger: about US$2.3B Use of proceeds: Fund tender offers for existing senior notes, pay related fees and expenses, and repay other outstanding debt | May 20, 2025 |
| Debt securities Announced: debt Use of proceeds: To fund, with cash on hand, the purchase price of notes bought back in the debt tender offers | May 19, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.3B | 16.5B | 15.8B | 14.9B | 15.9B | 16.7B | 16.9B | 18.3B | 21.9B | 21.9B |
| Cost of revenue | 8.32B | 8.48B | 8.20B | 7.95B | 8.28B | 8.93B | 9.35B | 9.97B | 11.2B | 10.3B |
| Gross profit | 8.94B | 8.06B | 7.64B | 6.97B | 7.59B | 7.73B | 7.54B | 8.30B | 10.6B | 11.7B |
| Research and development | 1.01B | 998.0M | 953.0M | 98.0M | 967.0M | 997.0M | 1.01B | 114.0M | 175.0M | 422.0M |
| Selling, general and administrative | 1.29B | 1.16B | 1.16B | 1.18B | 1.10B | 1.17B | 1.19B | 1.30B | 1.33B | 1.24B |
| Operating income | 2.16B | -303.0M | 433.0M | -2.20B | 1.72B | -3.57B | -443.0M | -1.64B | -17.5B | 2.15B |
| Depreciation and amortization | 1.00B | 1.06B | 1.15B | 1.31B | 1.33B | 1.56B | 1.72B | 1.84B | 2.11B | 1.52B |
| EBITDA | 3.16B | 756.0M | 1.59B | -889.0M | 3.05B | -2.02B | 1.28B | 205.0M | -15.4B | 3.68B |
| Interest expense | 916.0M | 1.00B | 1.03B | 930.0M | 891.0M | 901.0M | 822.0M | 920.0M | 875.0M | 546.0M |
| Income before tax | 1.22B | -1.28B | -624.0M | -3.16B | 658.0M | -4.41B | -1.26B | -2.60B | -18.4B | 824.0M |
| Income tax | -180.0M | 676.0M | -7.00M | -643.0M | 211.0M | -168.0M | -278.0M | -195.0M | -1.93B | 521.0M |
| Net income | 1.41B | -1.64B | -559.0M | -2.45B | 417.0M | -3.99B | -999.0M | -2.15B | -16.3B | 329.0M |
| Earnings per share, basic | 1.23 | -1.45 | -0.50 | -2.20 | 0.38 | -3.64 | -0.91 | -2.35 | -16.26 | 0.07 |
| Earnings per share, diluted | 1.21 | -1.45 | -0.50 | -2.20 | 0.38 | -3.64 | -0.91 | -2.35 | -16.26 | 0.07 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.56B | 3.30B | 3.23B | 2.80B | 2.17B | 2.18B | 1.98B | 1.78B | 963.0M | 988.0M |
| Short-term investments | 2.00M | 14.0M | 679.0M | |||||||
| Receivables | 3.71B | 3.06B | 3.41B | 3.70B | 4.53B | 4.58B | 5.68B | 5.82B | 7.13B | 7.52B |
| Inventory | 3.18B | 3.01B | 4.02B | 3.83B | 3.82B | 4.40B | 4.42B | 4.73B | 4.92B | 4.95B |
| Current assets | 13.9B | 12.6B | 12.5B | 12.1B | 12.6B | 13.0B | 13.5B | 13.8B | 15.4B | 17.2B |
| Property, plant and equipment | 4.08B | 4.58B | 5.75B | 5.74B | 5.98B | 6.30B | 6.44B | 6.87B | 7.67B | 8.07B |
| Goodwill | 16.0B | 16.0B | 17.2B | 17.2B | 17.6B | 20.6B | 24.8B | 24.9B | 28.4B | 44.4B |
| Total assets | 40.7B | 39.3B | 43.5B | 44.0B | 47.7B | 50.6B | 57.5B | 60.7B | 70.6B | 93.1B |
| Accounts payable | 225.0M | 158.0M | 108.0M | 1.89B | 1.69B | 1.76B | 1.72B | 1.85B | 2.07B | 2.16B |
| Current liabilities | 13.5B | 12.8B | 12.2B | 11.5B | 11.0B | 13.2B | 13.7B | 14.3B | 17.9B | 18.5B |
| Long-term debt | 15.0B | 16.0B | 18.2B | 19.1B | 21.6B | 22.7B | 24.6B | 26.7B | 28.8B | 32.5B |
| Total debt | 1.80B | 1.76B | 1.65B | 2.09B | 1.40B | 2.67B | 1.83B | 1.70B | 28.8B | 32.5B |
| Total liabilities | 32.8B | 33.6B | 35.4B | 35.4B | 36.4B | 39.6B | 42.4B | 44.9B | 51.9B | 58.1B |
| Shareholders' equity | 7.91B | 5.37B | 7.51B | 7.80B | 10.3B | 10.0B | 14.0B | 14.7B | 17.4B | 33.3B |
| Shares outstanding | 1.17B | 1.17B | 1.15B | 1.15B | 1.13B | 1.11B | 1.10B | 1.10B | 1.09B | 1.09B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.65B | 1.25B | 1.37B | 1.59B | 798.0M | 1.22B | 748.0M | 2.45B | 2.23B | 3.89B |
| Capital spending | -501.0M | -498.0M | -526.0M | -548.0M | -562.0M | -578.0M | -525.0M | -651.0M | -874.0M | -901.0M |
| Free cash flow | 1.15B | 749.0M | 842.0M | 1.04B | 236.0M | 638.0M | 223.0M | 1.79B | 1.35B | 2.99B |
| Cash from investing | 737.0M | 792.0M | 968.0M | 656.0M | 1.52B | 863.0M | 1.35B | 1.87B | 3.45B | -34.4B |
| Cash from financing | -2.15B | -1.79B | -1.91B | -1.49B | -2.17B | -1.89B | -1.93B | -3.35B | -5.75B | 25.2B |
| Dividends paid | -52.0M | -12.0M | -901.0M | -1.30B | ||||||
| Share buybacks | 0 | 0 | ||||||||
| Change in cash | 256.0M | 74.0M | 393.0M | 636.0M | 21.0M | 202.0M | 193.0M | 819.0M | -25.0M | -5.96B |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Nov 20, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 18, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Nov 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 10, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 4, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 29, 2026 | Management or board change | SEC |
| 3 · Initial statement of ownership | Oct 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 18, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 16, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Sep 14, 2026 | Other filings | SEC |
| 25-NSE | Sep 14, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Sep 11, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 11, 2026 | Current report | SEC |
| FWP · Free writing prospectus | Sep 10, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Sep 10, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Sep 8, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 3, 2026 | Current report | SEC |
| 8-K · Current report | Sep 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| F-6 POS | Jul 29, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 29, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 8-K · Current report | May 28, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 30, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Apr 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 29, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Mar 31, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Mar 31, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 31, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 26, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 9, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Feb 3, 2026 | Annual report | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 28, 2026 | Results | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 12, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 11, 2025 | Material contract | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 26, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 14, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Nov 6, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 6, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 1, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 22, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Teva Pharmaceutical Industries Limited’s releases · as of Sep 10, 2026
- Common shares
- 1,166,292,643
- Fully diluted
- 1,166,292,643
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,166,292,643 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,166,292,643 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Sol J. Barer Other companies: NexImmune, Inc. (Director · Feb 11, 2021 – Jul 5, 2023 · Past); Avalo Therapeutics, Inc. (Director · Feb 3, 2020 – Jun 15, 2021 · Past); PDS Biotechnology Corporation (Director · Sep 30, 2015 – Mar 15, 2019 · Past); CervoMed Inc. (Director · Nov 1, 2013 – Jul 24, 2014 · Past); Aevi Genomic Medicine LLC (Director · Jun 30, 2012 – Feb 3, 2020 · Past); InspireMD Inc. (Director · Jul 11, 2011 – Dec 7, 2016 · Past); Aegerion Pharmaceuticals Inc (Director · May 1, 2011 – Nov 29, 2016 · Past); Amicus Therapeutics Inc (Director · Jan 6, 2009 – Jun 9, 2016 · Past); Celgene Corporation (Director · Dec 31, 2005 – Jan 13, 2011 · Past) | Director · Since at least Jan 1, 2018 |
| Gabrielle Sulzberger Other companies: Eli Lilly and Company (Director · Since at least Jan 25, 2021); Mastercard Incorporated (Director · Since at least Dec 1, 2018); Warby Parker Inc. (Director · Sep 21, 2021 – Jun 7, 2024 · Past); Cerevel Therapeutics Holdings Inc (Director · Oct 27, 2020 – Aug 1, 2024 · Past); Brixmor Property Group Inc. (Director · Jun 8, 2015 – Jun 1, 2021 · Past); Stage Stores Inc (Director · Jun 7, 2012 – Jun 10, 2014 · Past); Whole Foods Market Inc (Director · Nov 16, 2011 – Aug 28, 2017 · Past) | Director · Jan 1, 2018 – Jan 1, 2018 · Past |
| Rosemary A. Crane Other companies: Certara, Inc. (Director · Since at least Jul 21, 2022); Tarsus Pharmaceuticals, Inc. (Director · Aug 11, 2021 – Jun 24, 2024 · Past); Catalent Inc (Director · Feb 16, 2018 – Oct 27, 2023 · Past); PDS Biotechnology Corporation (Director · Sep 18, 2017 – Mar 15, 2019 · Past); Unilife Corp (Director · Oct 28, 2016 – Oct 28, 2016 · Past) | Independent Director · Since at least Jan 1, 2018 |
| Edward Jordan Other companies: ALK-abello A/S Class B (Executive Vice President, Commercial Operations North America · Since at least Dec 1, 2025); DBV Technologies SA (EVP and head of Commercial Operations North America · Since at least Dec 1, 2025); Humanigen Inc (Chief Commercial Officer · Aug 24, 2020 – Jul 27, 2022 · Past); AMAG Pharmaceuticals Inc (SVP, Sales and Marketing · Feb 24, 2014 – Mar 3, 2015 · Past) | EVP and head of Commercial Operations North America · Since at least Dec 1, 2025 |
| Janet S. Vergis Other companies: Dentsply Sirona Inc. (Director and Science and Technology Committee Chair · Since at least Sep 25, 2019); Church & Dwight Company, Inc. (Director since 2014 · Since at least May 1, 2014); Amneal Pharmaceuticals, Inc. (Director · May 4, 2018 – May 6, 2019 · Past); Impax Laboratories Inc (Director · Oct 7, 2015 – May 4, 2018 · Past) | Director · Since at least Jun 9, 2020 |
| David R McAvoy Other companies: Fresh Tracks Therapeutics Inc. (Gen Counsel, CCO, & Secretary · Jan 24, 2023 – Oct 2, 2023 · Past); Brickell Biotech Inc (General Counsel and CCO · Aug 31, 2019 – May 5, 2022 · Past); Endocyte Inc (General Counsel · Nov 8, 2018 – Dec 21, 2018 · Past) | EVP, Chief Legal Officer · Since at least Mar 4, 2024 |
| Gerald Lieberman Other companies: Entera Bio Ltd. (Director · Since at least Jan 1, 2022); Forest Laboratories Inc (Director · Aug 23, 2011 – Jul 1, 2014 · Past); AllianceBernstein Holding L.P. (President and COO, Director · Feb 3, 2006 – Jan 23, 2009 · Past) | Independent Director · Since at least Jan 1, 2018 |
| Murray A Goldberg Other companies: Ayala Pharmaceuticals Inc (Director · May 7, 2020 – Jan 19, 2023 · Past); Aerie Pharmaceuticals Inc. (Director · Oct 25, 2013 – May 18, 2020 · Past); Regeneron Pharmaceuticals, Inc. (SVP Administration & Asst Secr · Jan 9, 2006 – Dec 16, 2014 · Past) | Director · Jan 1, 2018 – Jun 11, 2019 · Past |
| Brendan O’Grady Other companies: Nasus Pharma Ltd. (Chief Executive Officer, Director · Since at least Jul 27, 2026); Assertio Holdings, Inc. (CEO, Director · Since at least May 29, 2024) | EVP, North America Commercial · Jan 1, 2018 – Mar 4, 2021 · Past |
| Dan S Suesskind Other companies: Nano-X Imaging Ltd (Director · Since at least Mar 18, 2026); Ness Technologies Inc (Director · Jan 4, 2007 – Nov 6, 2007 · Past) | Director · Jan 1, 2018 – Jan 19, 2018 · Past |
All 45 people
| Person | Seat |
|---|---|
| Kare Schultz Other companies: Hims & Hers Health, Inc. (Director · Since at least Jul 16, 2024); International Flavors & Fragrances, Inc. (Director · Feb 1, 2021 – May 4, 2022 · Past) | President and CEO, Director · Jan 1, 2018 – Nov 1, 2022 · Past |
| Nechemia J. Peres Other companies: Via Transportation, Inc. (Managing Partner and Co-Founder of Pitango Venture Capital · Since at least Sep 11, 2025); Taboola.com Ltd. (Director · Since at least Jan 1, 2023) | Director · Jun 11, 2019 – Aug 4, 2022 · Past |
| Roberto A. Mignone Other companies: Guardant Health, Inc. (Director · Since at least Oct 21, 2024); Avanti Acquisition Corp (Director · Oct 1, 2020 – Oct 1, 2020 · Past) | Independent Director · Since at least Jan 1, 2018 |
| Tal Zaks Other companies: Moderna, Inc. (Chief Medical Officer · Dec 7, 2018 – Jun 30, 2021 · Past); Adaptimmune Therapeutics PLC (Director · Nov 14, 2016 – Jul 1, 2022 · Past) | Independent Director · Since at least Oct 1, 2021 |
| Amir Elstein Other companies: Tower Semiconductor Ltd. (Chairman of the Board · Since at least May 29, 2026) | Independent Director · Since at least Jan 1, 2018 |
| Chen Lichtenstein Other companies: ZIM Integrated Shipping Services Ltd. (President & Chief Executive Officer · Since at least Jun 1, 2026) | Independent Director · Since at least Dec 1, 2024 |
| David Matthew Stark Other companies: Assertio Holdings, Inc. (Director · Since at least Nov 7, 2024) | Exec. VP Chief Legal Officer · Jan 1, 2018 – Mar 6, 2023 · Past |
| Eric A. Hughes Other companies: Monte Rosa Therapeutics, Inc. (Executive Vice President, Global Research & Development Chief Medical Officer, Teva Pharmaceuticals · Since at least Dec 11, 2024) | "See ""Remarks""" · Since at least Aug 1, 2022 |
| Richard Francis Other companies: Mettler-Toledo International, Inc. (Director · Nov 9, 2023 – Nov 12, 2024 · Past) | President and CEO · Since at least Feb 15, 2024 |
| Varda Shalev Other companies: Pluri Inc. (Director · Jul 15, 2021 – Jul 15, 2021 · Past) | Director · Since at least Sep 1, 2023 |
| Amir Weiss | Chief Accounting Officer · Since at least Nov 24, 2021 |
| Andrew Weil | Chief Accounting Officer · Feb 15, 2021 – Nov 2, 2021 · Past |
| Angus Grant | EVP, Business Development · Aug 1, 2023 – Aug 9, 2024 · Past |
| Brian Savage | Interim Chief Legal Officer · Since at least Feb 11, 2026 |
| Carlo de Notaristefani | Executive VP Global Operations · Jan 1, 2018 – May 18, 2019 · Past |
| Christine Fox | EVP, U.S. Commercial · Since at least Nov 20, 2023 |
| Deborah A Griffin | Chief Accounting Officer · Jan 1, 2018 – Mar 17, 2020 · Past |
| Dov Bergwerk | Interim Chief Legal Officer · Since at least Oct 13, 2023 |
| Dvorah Haneviah | Until Jun 8, 2026 · Past |
| Eli Shani | EVP,Global Marketing&Portfolio · Aug 15, 2021 – Mar 3, 2023 · Past |
| Eliyahu Sharon Kalif | EVP, Chief Financial Officer · Since at least Dec 22, 2019 |
| Eric Drape | Executive VP Global Operations · Oct 2, 2019 – Mar 5, 2024 · Past |
| Evan Lippman | EVP, Business Development · Since at least Mar 31, 2025 |
| Galia Inbar | "See ""Remarks""" · Aug 15, 2021 – Mar 3, 2023 · Past |
| Gianfranco Nazzi | EVP, International Markets · Jan 1, 2018 – Mar 4, 2021 · Past |
| Hafrun Fridriksdottir | Executive VP, Global R&D · Jan 1, 2018 – May 17, 2022 · Past |
| Jean Michel Halfon | Director · Jan 1, 2018 – Aug 4, 2022 · Past |
| Mark Sabag | See "Remarks" · Since at least Feb 6, 2018 |
| Matthew Shields | EVP, Global Operations · Since at least Jun 3, 2024 |
| Perry D. Nisen | Director · Since at least Jun 5, 2021 |
| Placid Jover | "See ""Remarks""" · Since at least Aug 1, 2024 |
| Richard Daniell | EVP, Europe Commercial · Since at least Sep 9, 2019 |
| Ronit Satchi-Fainaro | Independent Director · Since at least Jun 11, 2019 |
| Sven Dethlefs | EVP, North America Commercial · Jan 1, 2018 – Mar 6, 2023 · Past |
| Vikki L Conway | "See ""Remarks""" · Sep 25, 2023 – May 13, 2024 · Past |
Log in to ask 6ix AI your own questions about Teva Pharmaceutical Industries Limited.